NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis $2.84 -0.01 (-0.18%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnership About Boundless Bio Stock (NASDAQ:BOLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boundless Bio alerts:Sign Up Key Stats Today's Range$2.83▼$2.8750-Day Range$2.41▼$3.0052-Week Range$0.96▼$3.16Volume9,736 shsAverage Volume579,010 shsMarket Capitalization$64.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 19% of companies evaluated by MarketBeat, and ranked 830th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingSell Consensus RatingBoundless Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageBoundless Bio has only been the subject of 2 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Boundless Bio is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Boundless Bio is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.94% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 1.92, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boundless Bio has recently increased by 208.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Boundless Bio this week, compared to 2 articles on an average week. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $510,654.00 in company stock, which represents 0.7876% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have bought 381.00% more of their company's stock than they have sold. Specifically, they have bought $644,685.00 in company stock and sold $134,031.00 in company stock.Percentage Held by Insiders23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBoundless Bio has minimal institutional ownership at this time.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLD Stock News HeadlinesCallio Therapeutics Appoints Zachary Hornby as Chief Executive OfficerSeptember 9 at 8:00 AM | globenewswire.comHalper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersJuly 2, 2026 | globenewswire.comBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's happening again this year. And next year. And the year after that. The people who understand this are already moving. In a free presentation I just recorded, I'm revealing what we call "The 2026 AI Gold Rush." The ONE AI-linked asset class the U.S. government has no choice but to fuel… and BlackRock, Goldman Sachs, and 170 public companies are already positioning into it. The same strategy that delivered 12,480% for Mastercard investors since its 2006 IPO. Sitting idle isn't "playing it safe." It's the most expensive decision you'll make this decade.September 10 at 1:00 AM | Decentralized Masters (Ad)Boundless Bio to merge with Serapha Bio in reverse merger; shares surgeJune 23, 2026 | msn.comBOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryJune 23, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)June 23, 2026 | prnewswire.comBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementJune 23, 2026 | globenewswire.comBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsMay 8, 2026 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How have BOLD shares performed this year? Boundless Bio's stock was trading at $1.18 at the beginning of 2026. Since then, BOLD shares have increased by 141.5% and is now trading at $2.85. How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) announced its earnings results on Friday, August, 7th. The biotechnology company reported ($1.06) earnings per share for the quarter. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an IPO on Thursday, March 28th 2024. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are Boundless Bio's major shareholders? Boundless Bio's top institutional investors include ARCH Venture Management LLC (11.84%), ADAR1 Capital Management LLC (8.65%), Wellington Management Group LLP (2.44%) and Stonepine Capital Management LLC (0.68%). Insiders that own company stock include Ra Capital Management, LP and Venture Fund Ix LP Arch. View institutional ownership trends. How do I buy shares of Boundless Bio? Shares of BOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/07/2026Today9/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BOLD's financial health is in the Green zone, according to TradeSmith. BOLD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLD CIK0001782303 Webwww.boundlessbio.com Phone(858) 766-9912FaxN/AEmployees64Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.89% Return on Assets-47.37% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio9.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.65Miscellaneous Outstanding Shares22,750,000Free Float17,493,000Market Cap$64.72 million OptionableNo Data Beta-0.03 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:BOLD) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...Eagle Publishing | SponsoredThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
